FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Carol Kemp

Research Profile

Chemicals & Drugs

Concepts & Ideas

Phenomena

Protein Binding

Physiology

Genes & Molecular Sequences

Molecular Structure

Living Beings

Escherichia coli

Co-author Network

Publications

TOP 3
Jinglei Yu; Mark Paine; Jean-Didier Marechal; Carol A Kemp; Clive J Ward; Simon Brown; Michael J Sutcliffe; Gordon Roberts; Elaine M Rankin; C Roland Wolf
In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide.
Lesley A McLaughlin; Mark Paine; Carol A Kemp; Jean-Didier Marechal; Jack U Flanagan; Clive J Ward; Michael J Sutcliffe; Gordon Roberts; C Roland Wolf
Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding.
Carol A Kemp; Jean-Didier Marechal; Michael J Sutcliffe
Progress in cytochrome P450 active site modeling.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Carol Kemp (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Jinglei Yu; Mark Paine; Jean-Didier Marechal; Carol A Kemp; Clive J Ward; Simon Brown; Michael J Sutcliffe; Gordon Roberts; Elaine M Rankin; C Roland Wolf
In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(8):1386-92.
2005: Lesley A McLaughlin; Mark Paine; Carol A Kemp; Jean-Didier Marechal; Jack U Flanagan; Clive J Ward; Michael J Sutcliffe; Gordon Roberts; C Roland Wolf
Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding.
The Journal of biological chemistry 2005;280(46):38617-24.
2005: Carol A Kemp; Jean-Didier Marechal; Michael J Sutcliffe
Progress in cytochrome P450 active site modeling.
Archives of biochemistry and biophysics 2005;433(2):361-8.
2004: Carol A Kemp; Jack U Flanagan; Annamaria J van Eldik; Jean-Didier Marechal; C Roland Wolf; Gordon Roberts; Mark Paine; Michael J Sutcliffe
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Journal of medicinal chemistry 2004;47(22):5340-6.
2004: Rachel J Lawson; David Leys; Michael J Sutcliffe; Carol A Kemp; Myles R Cheesman; Susan J Smith; John Clarkson; W Ewen Smith; Ihtshamul Haq; John B Perkins; Andrew W Munro
Thermodynamic and biophysical characterization of cytochrome P450 BioI from Bacillus subtilis.
Biochemistry 2004;43(39):12410-26.
2004: Jack U Flanagan; Jean-Didier Marechal; Richard Ward; Carol A Kemp; Lesley A McLaughlin; Michael J Sutcliffe; Gordon Roberts; Mark Paine; C Roland Wolf
Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
The Biochemical journal 2004;380(Pt 2):353-60.
2003: Andrew W Munro; Kirsty J McLean; Ker R Marshall; Ashley J Warman; G Lewis; Olivier Roitel; Michael J Sutcliffe; Carol A Kemp; S Modi; Nigel S Scrutton; David Leys
Cytochromes P450: novel drug targets in the war against multidrug-resistant Mycobacterium tuberculosis.
Biochemical Society transactions 2003;31(Pt 3):625-30.
2003: Mark Paine; Lesley A McLaughlin; Jack U Flanagan; Carol A Kemp; Michael J Sutcliffe; Gordon Roberts; C Roland Wolf
Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6.
The Journal of biological chemistry 2003;278(6):4021-7.
2002: Stewart B Kirton; Carol A Kemp; Nicholas P Tomkinson; Steven St-Gallay; Michael J Sutcliffe
Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6.
Proteins 2002;49(2):216-31.